Crystal Phase Refinement and Optical Features of Highly Efficient Green Light Radiating CaY(VO): Er Nanophosphors for Emerging Solid-state Lighting Applications.

CaY(VO) phosphor activated with Er ions have been developed by the urea-aided solution combustion technique. XRD profiles assisted with Rietveld refinement executed over-developed Er-activated CaY(VO) powder, revealed a trigonal phase with the R3c space group. The electron microscope techniques namely TEM and SEM characterize the size and surface-linked qualities of the developed nanopowder, respectively.

Crystal Chemistry and Photoluminescent Aspects of Bright Orange Light Emitting Sm- Activated BaBiVO Nanomaterials for Advanced Illuminating Applications.

In the present system, Sm activated BaBiVO nanomaterial series radiating orange-red light was developed via an efficient approach of solution combustion method. The structural examinations using XRD analysis indicate that the sample is crystallized into the monoclinic phase with the P21/a (14) space group. The elemental composition and morphological conduct were studied via energy dispersive spectroscopy (EDS) and scanning electron microscopy (SEM) respectively.

Combustion Synthesis and Study of Double Charge Transfer in Highly Efficient Cool White-emitting Dy Activated Vanadate-based Nanophosphor for Advanced Solid-state Lighting.

A series of CaGd(VO): Dy (x = 0.01-0.20) nanophosphor crystals emitting a cool white light were synthesized by solution combustion methodology.

Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials.

Background: Supportive care interventions used to manage chemotherapy-induced myelosuppression (CIM), including granulocyte colony-stimulating factors (G-CSFs), erythropoiesis-stimulating agents (ESAs), and red blood cell (RBC) transfusions, are burdensome to patients and associated with greater costs to health care systems. We evaluated the utilization of supportive care interventions and their relationship with the myeloprotective agent, trilaciclib.

Methods: Data were pooled from three independent randomized phase 2 clinical trials of trilaciclib or placebo administered prior to chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC).

Designing of emerald terbium (III) ions with β-ketocarboxylic acid and heterocyclic ancillary ligands for biological and optoelectronic applications.

A green and highly efficient grinding method was adopted to synthesize emerald terbium complexes with 1-cyclopropyl-6-fluro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid as the main organic ligand and 2,2'-bipyridyl, 1,10-phenanthroline, neocuproine, 5,6-dimethyl-1,10-phenanthroline and bathophenanthroline as ancillary ligands. Structural analysis of these complexes was executed via elemental, infrared and H-nuclear magnetic resonance analysis, which confirmed that the ligand coordinated to the metal ion through β-ketone and hydroxyl groups of carboxylic acid. Thermal stability of these complexes was investigated by study of thermogravimetric/derivative thermogravimetric analysis.

Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer.

Chemotherapy-induced myelosuppression is an acute, dose-limiting toxicity of chemotherapy regimens used in the treatment of extensive-stage small cell lung cancer (ES-SCLC). Trilaciclib protects haematopoietic stem and progenitor cells from chemotherapy-induced damage (myeloprotection). To assess the totality of the myeloprotective benefits of trilaciclib, including analysis of several clinically relevant but low-frequency events, an exploratory composite endpoint comprising five major adverse haematological events (MAHE) was prospectively defined: all-cause hospitalisations, all-cause chemotherapy dose reductions, febrile neutropenia (FN), prolonged severe neutropenia (SN) and red blood cell (RBC) transfusions on/after Week 5.

Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer.

Purpose: Trilaciclib is a first-in-class CDK4/6 inhibitor that transiently arrests hematopoietic stem and progenitor cells (HSPCs) in the G1 phase of the cell cycle to preserve them from chemotherapy-induced damage (myelopreservation). We report integrated analyses of preclinical and clinical data that informed selection of the recommended Phase II dose (RP2D) used in trilaciclib trials in extensive-stage small cell lung cancer (ES-SCLC).

Methods: A semi-mechanistic pharmacokinetic/pharmacodynamic (PK/PD) model developed from preclinical data guided selection of an optimal dose for G1 bone marrow arrest in a first-in-human Phase I study (G1T28-1-01).

CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy.

Background: Combination treatment with chemotherapy and immune checkpoint inhibitors (ICIs) has demonstrated meaningful clinical benefit to patients. However, chemotherapy-induced damage to the immune system can potentially diminish the efficacy of chemotherapy/ICI combinations. Trilaciclib, a highly potent, selective and reversible cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor in development to preserve hematopoietic stem and progenitor cells and immune system function during chemotherapy, has demonstrated proof of concept in recent clinical trials.

Screening for abdominal aortic aneurysms.

Ultrasonography remains the screening modality of choice for abdominal aortic aneurysms despite many advances in imaging modalities. Several randomized trials were performed that demonstrated the effectiveness of ultrasound-based screening to reduce aneurysm-related mortality. Ultrasound is both cost effective and low risk.

The impact of sex on angioplasty and primary stenting for femoropopliteal occlusive disease: results of the DURABILITY II trial.

Background: This study investigates the impact of sex on angioplasty and primary stenting for the treatment of claudicants with femoropopliteal occlusive disease (FPOD).

Methods: Two hundred eighty-seven patients enrolled in the Safety and Effectiveness Study of EverFlex Stent to Treat Symptomatic Femoral-popliteal Atherosclerosis (DURABILITY II) trial (a prospective, nonrandomized, core laboratory audited, and independently adjudicated investigational device exemption trial) were stratified by sex (190 men and 97 women) and reviewed.

Results: Women presented with FPOD at an older age than men (71.

Current endovascular treatment of infrarenal abdominal aortic aneurysms and future directions.

The paradigm in elective surgical management of infrarenal abdominal aortic aneurysms (AAAs) has quickly shifted from major open surgical repairs to less invasive, endovascular procedures. In the last few years, there have been numerous advancements to commercially available devices making the endovascular approach more attractive and efficacious. This review serves to detail the similarities, differences, advantages, and disadvantages of currently available endovascular stent-grafts as well as preview future and emerging technologies in endovascular aortic therapies.

The effect of statin use on embolic potential during carotid angioplasty and stenting.

Background: Statin use results in atherosclerotic plaque stabilization. We sought to determine the effects of statins on the size and number of embolic particles generated during carotid artery stenting (CAS).

Methods: Embolic debris from carotid filters following CAS was analyzed using photomicroscopy and imaging software.

A novel approach to the management of an inflammatory abdominal aortic aneurysm associated with crossed-fused renal ectopia.

Background: Crossed-fused renal ectopia is a rare anomaly that poses a therapeutic challenge in the management of abdominal aortic aneurysms (AAAs). Such challenges include preservation of renal blood flow in the setting of multiple aberrant renal arteries and ureteral anomalies. Several surgical approaches to this dilemma, including the use of traditional surgical techniques, have been described in the literature.

Predicting embolic potential during carotid angioplasty and stenting: analysis of captured particulate debris, ultrasound characteristics, and prior carotid endarterectomy.

Introduction: Extracranial carotid stenoses exhibit significant variance in embolic potential, with restenotic lesions having a particularly low propensity for embolization. This study sought to identify characteristics associated with increased generation of embolic debris during carotid angioplasty and stenting (CAS).

Methods: Captured particulate was available for analysis in 56 consecutive patients.

Tips and techniques in carotid artery stenting.

Significant technical advances have made carotid artery stenting an option for high-risk patients. These advances bring forth new challenges that must be overcome. Preprocedural planning is essential for optimal outcome for every patient given the high risk for significant neurologic complications.